Ocular diseases dominated by neovascularization, such as age-related macular degeneration (AMD), retinal vein occlusions, and diabetic retinopathy (DR), often culminate in severe visual loss and ultimately blindness. In most of these conditions, ischemic retinal areas produce abnormal amounts of angiogenic growth factors that induce excessive angiogenesis, overwhelming the effects of natural angiogenesis inhibitors ([@bibr101-0022155412467635]). The newly formed vessels occur as part of wound-healing responses and usually do not restore tissue integrity. Vision is disturbed when bleeding occurs by secondary macular edema, or when vessels finally grow into normally avascular transparent tissues such as the fovea and vitreous and develop into scar tissue ([@bibr74-0022155412467635]). The most widely used therapeutic target in treating ocular neovascularization is vascular endothelial growth factor-A (VEGF-A) ([@bibr101-0022155412467635]). Currently, VEGF-A antagonists are standard care in the treatment of exudative AMD and have been found to be a valuable additional treatment strategy in several other vascular retinal diseases ([@bibr77-0022155412467635]).

VEGF and other endogenous factors that can drive angiogenesis have been studied in detail in the past decades, but our understanding of the complex molecular mechanisms that regulate endothelial cell differentiation during sprout formation has advanced only recently. Sprouting angiogenesis requires hierarchical organization and activation of endothelial cells from preexisting blood vessels to form new vessels, while at the same time the majority of endothelial cells need to remain quiescent. This hierarchical organization is mainly mediated by specialized motile endothelial cells located at the tips of growing vessels, termed *tip cells*. Simultaneously, complex interactions occur between endothelial cells and supporting cells in the microenvironment via angiogenic growth factors and inhibitors ([@bibr86-0022155412467635]). In the retina, supporting cells are mainly pericytes that envelope retinal capillaries to provide vessel stability.

Tip cells have a unique functional and molecular signature and are therefore an attractive target for therapeutic modulation of angiogenesis. The relative ease of accessibility for imaging and intervention makes the retina ideally suitable for research on tip cells ([@bibr86-0022155412467635]), when compared with models of tumor angiogenesis (reviewed in [@bibr16-0022155412467635]). This has spurred intensive research into the complex molecular mechanisms that regulate endothelial differentiation and has led to the screening of potential therapeutic agents. In fact, many studies on molecular targets of tip cells in the field of tumor angiogenesis also included mouse models of retinal angiogenesis. However, to date, no single antibody can serve as a unique marker of endothelial tip cells in vivo.

A recent study from our group demonstrated that cells with virtually all the known properties of tip cells are present in two-dimensional vascular endothelial cell cultures and that this subpopulation of cells can be isolated on the basis of CD34 expression ([@bibr83-0022155412467635]). This in vitro tip cell model has opened alternative avenues for the study of molecular processes and functions in tip cells in angiogenesis and has allowed characterization of the full transcriptome of tip cells in vitro. This has identified a large number of tip cell-associated genes not previously published, in addition to the known genes previously associated with tip cells in vivo. The present review translates these findings to the context of angiogenesis in proliferative retinal diseases, as well as to the possible implications of these findings for development of therapeutic strategies.

Endothelial Cell Differentiation in Vascular Sprouts {#section1-0022155412467635}
====================================================

Angiogenesis is tightly controlled by closely interacting angiogenic and angiostatic factors, and their balance ultimately determines if, where, and when the "angiogenic switch" is turned on, with angiogenesis as the result ([@bibr101-0022155412467635]). The angiogenic switch occurs only in a small subset of endothelial cells without disrupting the integrity of the preexisting vascular network. Subsequently, these endothelial cells differentiate to enable migration, proliferation, lumen formation, and the formation of vessel walls. These cellular processes are not taking place simultaneously in all cells involved. Instead, several highly specialized endothelial phenotypes with distinct functions form a vascular sprout in an orchestrated manner (reviewed in [@bibr42-0022155412467635]).

First, a single tip cell emerges from the existing blood vessel and becomes the leading cell of the sprouting vessel. Tip cells dynamically extend long filopodial protrusions in a polarized way, migrate into the extracellular matrix, and sense their environment for attractive and repulsive signals for guidance ([Fig. 1](#fig1-0022155412467635){ref-type="fig"}) ([@bibr53-0022155412467635]; [@bibr78-0022155412467635]; [@bibr61-0022155412467635]; [@bibr75-0022155412467635]; [@bibr99-0022155412467635], [@bibr100-0022155412467635]; [@bibr34-0022155412467635]). Tip cells have a minimal proliferation rate or do not proliferate at all, are not involved in the formation of the vessel lumen, and actively recruit non-vascular cells, including pericytes.

![Concept of endothelial cell differentiation during angiogenesis. Angiogenic sprouts are formed by a subset of specialized endothelial cell phenotypes (green), each with a distinct cellular fate. Pericytes (blue) are instantly recruited to ensheathe the sprouting vessel and to produce a basal lamina (red).](10.1369_0022155412467635-fig1){#fig1-0022155412467635}

Second, other endothelial cells, directly following the migrating tip cell, differentiate under the influence of the tip cell into *stalk cells* that proliferate and bridge the gap between the tip cell and the parent vasculature. Stalk cells generate the blood vessel lumen, a process called *lumenogenesis* (reviewed in [@bibr46-0022155412467635]). Together, the tip and stalk cell phenotypes form a vascular sprout, which grows toward an angiogenic stimulus, in response to chemical cues, mechanical factors, and some degree of random motility.

Third, endothelial cells behind the stalk cells differentiate into *phalanx cells* and align in a smooth cobblestone monolayer, becoming the most inner cell layer in the new blood vessel, where they no longer proliferate (reviewed in [@bibr19-0022155412467635]). Both stalk and phalanx cells express tight junctions and associate with supporting vascular smooth muscle cells or pericytes, depending on the type of vascular bed. The retinal vasculature appears to be particularly dependent on pericytes, and defective pericyte recruitment affects the retina more than other tissues (reviewed in [@bibr27-0022155412467635]). Finally, endothelial tip cells of two sprouts come together and form new blood vessels, a process called *anastomosis*, mediated by tissue-resident macrophages ([@bibr29-0022155412467635]).

Angiogenic Tip Cells in the Retina {#section2-0022155412467635}
==================================

Embryo {#section3-0022155412467635}
------

Tip cells are distinguished predominantly on the basis of their location and specific morphology. Isolectin-B4 and anti-CD34, anti-VEGF receptor 3 (VEGFR3), and anti-laminin antibodies enable visualization of tip cells and their filopodia in angiogenic tissues, such as the developing retina. In these tissues, tip cells are found at the edge of the expanding vascular plexus, extending numerous filopodia that probe the environment ([Fig. 2A](#fig2-0022155412467635){ref-type="fig"}) ([@bibr53-0022155412467635]; [@bibr78-0022155412467635]; [@bibr61-0022155412467635]; [@bibr75-0022155412467635]; [@bibr45-0022155412467635]; [@bibr34-0022155412467635]; [@bibr99-0022155412467635], [@bibr100-0022155412467635]). However, most of these antibodies also stain stalk cells and phalanx cells. To date, a single antibody that can be used as a specific marker of endothelial tip cells in vivo has not been identified.

![Tip cells are actively generated in physiological and pathological conditions of the retina. Confocal images of blood vessels from mouse retinas stained with Alexa 488-conjugated isolectin-B4. (A1, A2) Retinal wholemount from postnatal day 5 shows that the superficial vascular plexus is formed by radial outgrowth of vessels from the optic nerve into the periphery. (A1) Tip cells are located at the angiogenic front (arrowheads). Scale bar = 50 µm. (A2) High magnification of tip cells with their typical morphology (highly polarized nature and numerous filopodia probing the environment). Scale bar = 20 µm. (B1, B2) Retinal wholemount from postnatal day 17 in the oxygen-induced retinopathy model when the maximum severity of the pathological neovascularization is reached during relative hypoxia. (B1) Pathological neovessels leave the retina and grow into the vitreous cavity to form unorganized, small-caliber vessels, termed *preretinal tufts* (arrows). Scale bar = 500 µm. (B2) High magnification of an epiretinal tuft that is formed by activated endothelial cells that extend numerous filopodia in all directions. Scale bar = 20 µm.](10.1369_0022155412467635-fig2){#fig2-0022155412467635}

In contrast to humans, where development of the intraretinal vasculature is completed at the time of birth, retinal vascularization in mice occurs postnatally, which enables the study of various stages of vessel network formation in neonatal animals. The mouse retina has therefore contri-buted significantly to our understanding of mechanisms of endothelial cell differentiation during angiogenic sprouting ([@bibr45-0022155412467635]; [@bibr34-0022155412467635]; [@bibr16-0022155412467635]). In the first week after birth, retinal vessels immediately emerge from the optic nerve head, grow radially toward the retinal periphery, and form the laminar superficial vascular plexus. In the second postnatal week, branches of the superficial vessels sprout to generate the deep vascular plexus. A tertiary intermediate vascular plexus is formed in the third postnatal week. Tip cells have been found in all areas of this active retinal angiogenic network formation, indicating that tip cells are actively generated during physiological retinal neovascularization ([@bibr29-0022155412467635]; [@bibr13-0022155412467635]; [@bibr12-0022155412467635]).

During retinal development, the vascular and neuroretinal cell systems display a high degree of crosstalk and depend on each other functionally. Regulatory mechanisms respond to altered oxygen profiles during retinal development to induce a controlled and organized angiogenic response (reviewed in [@bibr12-0022155412467635]). The neuroretina acts primarily as an oxygen sensor, through the transcription factor hypoxia-inducible factor 1 alpha subunit (HIF-1α), which is required for proper vascular patterning in the retina ([@bibr13-0022155412467635]; [@bibr63-0022155412467635]). In addition, an astrocytic network is established in the retina and serves as a template over which filopodia-mediated tip cell migration takes place ([@bibr23-0022155412467635]).

Pathological Conditions {#section4-0022155412467635}
-----------------------

The typical morphological aspects of tip cells (highly polarized nature and numerous filopodia probing the environment) were also found in specimens of human pathological retinal neovascularization ([@bibr75-0022155412467635]; [@bibr74-0022155412467635]) and in tumors ([@bibr75-0022155412467635]). Compared with physiological angiogenesis, both the number of tip cells as well as the number of filopodial protrusions per tip cell is highly increased in areas of pathological angiogenesis. Several in vivo models have been developed to study mechanisms of pathological neovascularization in retinal diseases ([@bibr36-0022155412467635]). One of the major models is oxygen-induced retinopathy in mice: an acute biphasic model of preretinal neovascularization associated with ischemia in the retina that develops after a period of experimental hyperoxia ([@bibr84-0022155412467635]; [@bibr86-0022155412467635]). These pathological newly formed vessels grow outside the highly organized layered structure of the retina into the normally avascular vitreous cavity to form disorganized, small-sized vascular structures, termed *preretinal tufts*. The tufts consist of activated endothelial cells and resemble pathological neovascularization observed in human proliferative retinopathies ([@bibr86-0022155412467635]). It has been shown that most endothelial cells from these tufts extend numerous filopodia ([@bibr10-0022155412467635]; [@bibr32-0022155412467635]; [@bibr38-0022155412467635]; [@bibr106-0022155412467635]). In contrast to tip cells in developmental angiogenesis, pathologically generated tip cells extend shorter filopodia, which grow in all directions ([Fig. 2B](#fig2-0022155412467635){ref-type="fig"}). In addition to the formation of these "pathological" neovascular tufts, angiogenesis occurs also within the retina in this model, restoring the vasculature of the ischemic non-perfused areas.

What Controls the Differentiation of Tip Cells and Stalk Cells? {#section5-0022155412467635}
===============================================================

VEGF Induces the Tip Cell Phenotype {#section6-0022155412467635}
-----------------------------------

The VEGF family of growth factors are key molecules for initiation and direction of blood vessel sprouting. In mammals, the VEGF family includes VEGF-A, VEGF-B, placenta growth factor (PlGF), VEGF-C, and VEGF-D (reviewed in [@bibr101-0022155412467635]). It is widely accepted that VEGF-A is crucial for both vasculogenesis and angiogenesis: loss of only a single allele in mice or zebrafish is lethal due to severe vascular defects and abnormalities ([@bibr15-0022155412467635]). Tip cells, stalk cells, and phalanx cells are all dependent on the binding of VEGF to cell membrane VEGF receptors (VEGFRs). Interestingly, all three phenotypes react in distinct ways to VEGF-A signaling: Tip cells start to migrate and extend filopodia, stalk cells undergo proliferation, and phalanx cells need low levels of VEGF-A for survival. A first explanation for these multiple complex roles of VEGF-A in morphogenic events was based on observations showing that local concentrations of VEGF-A vary in areas of angiogenic tissues and that endothelial cells differentiate into tip cells and remain tip cells only when VEGF-A levels are above a certain threshold.^9^ Hence, endothelial cells exposed to the highest VEGF-A levels are the ones that likely become tip cells. Furthermore, the activation of cell membrane receptors has differential effects in tip cells, stalk cells, and phalanx cells, most likely due to combinations with other signals. VEGFs bind selectively to three distinct receptors with different affinities: VEGFR1, also known as FLT1; VEGFR2, also known as KDR or FLK1; and VEGFR3, also known as FLT4 ([@bibr101-0022155412467635]). VEGFR2 is considered to be the major receptor responsible for mediating the angiogenic effects of VEGF-A. Relative expression levels of VEGFR2 play a crucial role in endothelial cell differentiation: the highest levels of messenger RNA and protein of VEGFR2 were found in tip cells ([Fig. 3](#fig3-0022155412467635){ref-type="fig"}) ([@bibr34-0022155412467635]).Furthermore, tip cells and their filopodia express VEGFR3 ([@bibr99-0022155412467635]; [@bibr82-0022155412467635]; [@bibr93-0022155412467635], [@bibr92-0022155412467635]; [@bibr5-0022155412467635]). Activation of VEGFR3 by its ligand, VEGF-C, but also ligand-independent VEGFR3 activation allows angiogenic vessel growth ([@bibr33-0022155412467635]; [@bibr105-0022155412467635]; [@bibr92-0022155412467635]), even in the absence of VEGF-A/VEGFR2 signaling ([@bibr5-0022155412467635]). VEGFR1 is expressed in tip, stalk, and phalanx cells. A recent study in zebrafish showed that loss of VEGFR1 signaling increases the number of tip cells, suggesting that VEGFR1 acts as a negative regulator of tip cell differentiation and branching ([@bibr55-0022155412467635]).

![Schematic representation of the VEGF-DLL4-Notch signaling pathway in angiogenic sprouts. Tip cells express vascular endothelial growth factor receptor 2 (VEGFR2) and vascular endothelial growth factor receptor 3 (VEGFR3) together with several co-receptors, including neuropilin-1 (NRP1), to sense for vascular endothelial growth factor (VEGF) signals. Extracellular gradients of VEGF provide a template for tip cell attraction. Upon activation, tip cells express DLL4, which binds to Notch receptors on follower stalk cells. In stalk cells, Notch is cleaved by gamma-secretase, releasing the Notch intracellular domain (NICD), which dampens the expression of VEGFR2 and VEGFR3, as well as increases VEGFR1 expression. sVEGFR1 is released by stalk cells and binds to VEGF molecules to block local VEGF signaling. Jagged1 is expressed by stalk cells and negatively regulates Notch activity in tip cells.](10.1369_0022155412467635-fig3){#fig3-0022155412467635}

VEGF/VEGFR signaling complexes also include co-receptors such as neuropilin-1 (NRP1) and NRP2. A co-receptor is a cell surface receptor that binds a signaling molecule in addition to a primary receptor, facilitating ligand recognition, and inducing specific internal cellular signaling. The formation of VEGFR2/NRP complexes amplifies VEGF-induced angiogenesis ([@bibr35-0022155412467635]; [@bibr93-0022155412467635]). The filopodia of tip cells are positive for both NRP1 and NRP2 ([@bibr35-0022155412467635]). Another co-factor of VEGF signaling in tip cell induction is ephrin-B2 (EFNB2), a transmembrane ligand for EphB receptor tyrosine kinases ([@bibr9-0022155412467635]). EFNB2 controls VEGFR2 internalization, which is necessary for activation and downstream signaling of the receptor, and is required for VEGF-induced tip cell filopodia extension ([@bibr73-0022155412467635]; [@bibr98-0022155412467635]). Finally, after activation by VEGF-A or VEGF-C, tip cells can form heterodimers of VEGFR2 and VEGFR3 that positively regulate angiogenic sprouting ([@bibr66-0022155412467635]; [@bibr105-0022155412467635]). Thus, once they have been induced by VEGF-A, tip cells become much more sensitive to VEGF than adjacent stalk cells. Endothelial cells determine the appropriate response to VEGF activation via crosstalk between different VEGF receptors in combination with the activity of co-receptors and other signaling molecules.

The hierarchical non-symmetric relations between endothelial cells in sprouts are dynamic, and differentiation of tip cells is reversible. Tip and stalk cells continuously compete for the tip cell position, controlled by differential VEGFR expression levels in individual endothelial cells ([@bibr48-0022155412467635]). A tip cell erroneously migrating toward an area containing lower levels of VEGF-A may lose sensitivity to VEGF-A, allowing the challenging neighbor to gain a competitive advantage ([@bibr48-0022155412467635]). Because the tip cell position seems to be controlled by survival and local adaptation, one can easily speculate that the tip cell phenotype is dominant over others, implicating that the tip cell controls adjacent endothelial cells and other cell types in terms of cell fate.

Lateral Cell-Cell Inhibition Limits Tip Cell Formation {#section7-0022155412467635}
------------------------------------------------------

Differentiation of endothelial tip cells from a population of quiescent endothelial cells has to be tightly regulated because excessive tip cell formation results in a poorly patterned, hyperdense vessel network that may not be functional. Therefore, tip cells signal to their adjacent endothelial cells to downregulate their tip cell phenotype and maintain the proliferative stalk cell phenotype. As stated above, relative expression levels of VEGFR2 and other receptors ultimately determine whether a cell becomes a tip cell or not. In tip cells, VEGFR2 signaling induces the expression of the Notch ligand delta-like 4 (DLL4), which is then transported to the cell membrane and binds to Notch receptors on adjacent endothelial cells ([Fig. 3](#fig3-0022155412467635){ref-type="fig"}). Upon DLL4 binding, Notch is cleaved, generating the Notch intracellular domain, which acts as a transcriptional regulator and dampens VEGFR2, VEGFR3, and NRP1 expression in these future stalk cells, as well as induces the transcription of VEGFR1 and its soluble splice variant sVEGFR1 ([@bibr82-0022155412467635]; [@bibr90-0022155412467635]; [@bibr41-0022155412467635]; [@bibr93-0022155412467635]). sVEGFR1 is secreted by stalk cells and binds to VEGF-A in the extracellular matrix, decreasing local levels of available VEGF-A ([@bibr41-0022155412467635]). Secretion of sVEGFR1 therefore decreases VEGF/VEGFR2 signaling in stalk cells, consolidating the stalk cell phenotype.

Cell-matrix interactions mediated by laminin/integrin-induced signaling are necessary to induce physiologically functional levels of DLL4 expression in tip cells ([@bibr28-0022155412467635]; [@bibr87-0022155412467635]). VEGF treatment stimulates laminin production, leading to integrin signaling and induction of DLL4. Apparently, the extracellular matrix is important for promotion of DLL4 expression in endothelial tip cells. On the other hand, a recent study showed that VEGF-A/VEGFR2 signaling is not essential for DLL4 expression in tip cells ([@bibr5-0022155412467635]).

Another critical component in tip cell-stalk cell Notch signaling is Jagged1, which is abundantly expressed in stalk cells ([@bibr43-0022155412467635]; [@bibr4-0022155412467635]). Jagged1 negatively regulates Notch activity by antagonizing DLL4-induced Notch activation. Because Notch is expressed in both tip cells and stalk cells, it is likely that Jagged1 from stalk cells binds to Notch on adjacent tip cells, thereby inactivating this signaling pathway in tip cells ([@bibr4-0022155412467635]; [@bibr89-0022155412467635]). Jagged1 also counteracts DLL4-Notch signaling interactions between adjacent stalk cells, which may help to sustain low VEGFR expression levels in stalk cells and keep them sensitive for VEGF-A to promote stalk cell proliferation ([Fig. 3](#fig3-0022155412467635){ref-type="fig"}). However, the exact role of these DLL4/Jagged1 interactions in angiogenesis is still unclear.

A third Notch-ligand, DLL1, was also shown to be involved in endothelial cell differentiation but not via lateral inhibition. DLL1 is secreted by non-vascular cells in the retina during development and induces VEGFR3 and EFNB2 expression in endothelial tip cells ([@bibr64-0022155412467635]). DLL1 is a less potent Notch activator than DLL4; induction of DLL4 in tip cells that binds to Notch on stalk cells therefore results in less sensitivity of the Notch receptor for DLL1 in stalk cells. Taken together, these data emphasize that specific Notch ligands, in crosstalk with VEGF, exert diverse effects in endothelial cell differentiation during angiogenesis and that both tip and stalk cells can use these different effects to control each other.

Tip Cells Control Sprout Behavior through Secretion of Specific Molecules {#section8-0022155412467635}
-------------------------------------------------------------------------

If and how tip cells signal to stalk cells that are not in direct cell-cell contact is less well understood. Several recent studies attempted to analyze the expression profiles of endothelial tip cells and identified a number of tip cell-associated genes that are specifically expressed by these cells ([@bibr41-0022155412467635]; [@bibr20-0022155412467635]; [@bibr88-0022155412467635]; [@bibr83-0022155412467635]). These studies not only expand the tip cell gene expression profile but also contribute to our understanding of tip cell biology and tip cell-specific functions. Surprisingly, the largest cluster of upregulated genes in tip cells encodes for proteins that are secreted, including chemokines, proteases, adrenomedullin (ADM), platelet-derived growth factor-B (PDGF-B), angiopoietin-2 (ANG2), apelin (APLN), insulin-like growth factor binding proteins (IGFBPs), and endothelial specific molecule-1 ([@bibr20-0022155412467635]; [@bibr88-0022155412467635]; [@bibr83-0022155412467635]). These molecules can potentially regulate many aspects of angiogenesis such as interactions with astrocytes, microglial cells, pericytes, and endothelial stalk cells. Secretion of molecules further indicates the dominant role of the tip cell over other endothelial cell phenotypes and other cell types. Some of these gene products have been studied for their functional role in angiogenesis. However, extensive further studies are necessary to elucidate their exact functions in tip cell biology. It may be assumed that tip cells secrete regulatory proteins while creating a path throughout the extracellular matrix to control behavior of trailing stalk cells and pericytes during angiogenesis.

Another mechanism of distant signaling by tip cells has been suggested on the basis of secretion of exosomes containing DLL4, indicating an additional long-range signaling mechanism involved in tip cell differentiation ([@bibr80-0022155412467635]). These exosomes appeared to be able to confer a tip cell phenotype on recipient cells and may represent a mechanism by which stalk cell differentiation is restricted so that tip cell formation can recur. However, the exact role of these exosomes during angiogenesis in vivo is not clear.

Modulation of Tip Cells by MicroRNAs {#section9-0022155412467635}
------------------------------------

MicroRNAs (miRNA) are a class of short non-coding RNA molecules that bind to complementary sequences of target messenger RNA transcripts (mRNAs) to regulate activity of transcripts at the posttranscriptional level. Because relative gene expression levels are crucial in the dynamic competition between tip cells and stalk cells, miRNAs may function as internal mechanisms to rapidly change the effects of gene expression levels in these cells. There is increasing evidence that miRNAs play important roles in vascular development as well as in vascular diseases, including DR and AMD ([@bibr81-0022155412467635]; [@bibr54-0022155412467635]). In addition, multiple miRNAs have been implicated in controlling the angiogenic response of endothelial cells to various growth factors (reviewed in [@bibr11-0022155412467635]).

Two recent studies identified miR-221 and miR-27b to be important in regulation of tip cell functioning during angiogenesis in zebrafish models ([@bibr7-0022155412467635]; [@bibr65-0022155412467635]). miR-221 was found to repress two distinct pathways in sprouting endothelial cells: the phosphoinositide-3-kinase, regulatory subunit 1 alpha (PIK3R1) complex and cell cycle progression via cyclin-dependent kinase inhibitor 1b (CDKN1B). Downregulation of CDKNB1 and promotion of optimal PI3K output by reduction of PIK3R1 induced tip cell migration and proliferation ([@bibr65-0022155412467635]). Furthermore, miR-221 levels were found to be negatively regulated downstream of DLL4/Notch signaling in stalk cells. Thus, miR-221 enables endothelial cells to dynamically respond to pro-angiogenic cues.

miR-27b was found to promote microvessel sprouting and branching by repressing DLL4 and therefore increasing the number of endothelial cells that have the tip cell phenotype ([@bibr7-0022155412467635]). Blockade of miR-27b impaired sprouting and induced the generation of large open vessels in tumors ([@bibr7-0022155412467635]).

miRNA-126 is regarded as one of the most important microRNAs governing vascular integrity and angiogenesis by regulating the signaling of angiogenic growth factors ([@bibr30-0022155412467635]). Retinal levels of miR-126 were found to be decreased in the mouse model of oxygen-induced retinopathy, and intravitreal injection of miR-126 was found to reduce pathological neovascularization in this model ([@bibr2-0022155412467635]). Both miR-27b and miR-126 share common target genes, suggesting that miR-126 regulates vascular sprouting and tip cell formation ([@bibr56-0022155412467635]). These findings suggest that miRNAs mediate a fine balance between inducers and suppressors of endothelial differentiation, as well as tip cell- and stalk cell-specific behavior in angiogenic sprouts.

Functional Characteristics of Endothelial Tip Cells {#section10-0022155412467635}
===================================================

Migration and Searching for Guidance Cues {#section11-0022155412467635}
-----------------------------------------

Tip cells are known to express receptors for guidance cues, such as the Netrin receptor uncoordinated-5B (UNC5B) and NRPs, by which they pick up attractive or repulsive signals from the tissue environment and translate them into a dynamic process of adhesion and detachment, leading to directed migration. In this process, the tip cell forms filopodia and lamellipodia (reviewed in [@bibr62-0022155412467635]). Filopodia are long, spiky plasma membrane protrusions containing tight parallel bundles of filamentous actin, and they function as antennae with which tip cells probe their environment. Lamellipodia are short protrusions that contain a highly branched actin network and are located at the front edge of the cell. In lamellipodia, the intracellular cytoskeleton is connected to the extracellular matrix via adhesion molecules, allowing stress fibers of actin/myosin filaments to pull the cell forward. The main regulators of filopodia and lamellipodia formation are members of the Rho small GTPases, which are induced by VEGF/VEGFR2 signaling in tip cells ([@bibr59-0022155412467635]; [@bibr47-0022155412467635]). An extracellular VEGF-A gradient appears to be a strong attractant for migrating endothelial cells via binding to VEGFR2 and NRPs, which are prominently present on tip cell filopodia ([@bibr34-0022155412467635], [@bibr35-0022155412467635]; [@bibr59-0022155412467635]). An important biological property of the different VEGF-A isoforms is their varying heparin- and heparansulfate-binding capacity (reviewed in [@bibr101-0022155412467635]). The larger VEGF-A isoforms bind very tightly to heparin and thus remain sequestered in the extracellular matrix, whereas the shorter VEGF-A isoforms diffuse freely. VEGF-A~189~ and VEGF-A~165~ promote polarized extension of tip cell filopodia, whereas VEGF-A~121~ induces endothelial cell proliferation but has little effect on tip cell guidance (reviewed in [@bibr14-0022155412467635]).

Endothelial tip cells function in a remarkably similar way as axonal growth cones (reviewed in [@bibr14-0022155412467635]; [@bibr24-0022155412467635]; [@bibr1-0022155412467635]). Blood vessels and nerve fibers course throughout the body alongside one another, and it has been reported that, during embryogenesis, their patterning is guided in large part by similar attractive and repulsive guidance cues. Thus far, four major families of receptors have been shown to regulate guidance events during axonal and vascular morphogenesis: plexin/NRP complexes with their ligands class 3 Semaphorins, UNC5 family and "deleted in colorectal cancer" (DCC) with their ligands Netrins, "roundabout" (ROBO) with their ligands Slits, and EPH and their ligands Ephrins ([Table 1](#table1-0022155412467635){ref-type="table"}) ([@bibr14-0022155412467635]).

###### 

Molecular Regulators of Tip Cell Behavior and Differentiation

  Genes Upregulated in Tip Cells   Description              Function(s)
  -------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------------------
  VEGFR2                           Transmembrane receptor   Tip cell activation, filopodia formation, tip cell guidance (attractive), migration
  VEGFR3                           Transmembrane receptor   Tip cell activation, tip cell guidance (attractive), modulates vascular endothelial growth factor receptor 2 (VEGFR2) signaling
  NRP1                             Transmembrane receptor   Increased VEGF co-receptor, VEGFR2 and VEGFR3 signaling
  PDGFB                            Secreted molecule        Pericyte recruitment
  DLL4                             Transmembrane protein    Tip cell-phenotype suppression in stalk cells
  ANGPT2                           Secreted molecule        Vessel destabilization (only in the presence of VEGF), stalk cell proliferation
  APLN                             Secreted molecule        Stalk cell proliferation
  UNC5B                            Transmembrane receptor   Tip cell guidance (repulsive)
  PLXND1                           Transmembrane receptor   Tip cell guidance (repulsive)
  EFNB2                            Transmembrane protein    VEGFR2 internalization, filopodia formation, migration
  MMP14                            Protease                 Pericellular collagenase, extracellular matrix remodeling
  CXCR4                            Chemokine receptor       Tip cell activation, mediation of tip cell morphology, tip cell guidance (attractive)

Extracellular Matrix and Basal Lamina Interactions {#section12-0022155412467635}
--------------------------------------------------

To allow tip cells to penetrate avascular tissues, the basal lamina and extracellular matrix barriers that ensheathe the preexisting capillary have to be degraded. Therefore, tip cells acquire a proteolytic phenotype and secrete proteases, leading to remodeling of the extracellular matrix. First, the binding of tip cells to laminin in the basal lamina is disrupted, which activates signaling cascades that lead to reorganization of the cytoskeleton and a change in cell shape. The family of matrix metalloproteinases (MMPs) consist of 26 members, and the key players of the MMP family that participate in tip cell functioning and ocular angiogenesis are MMP2, MMP9, and MMP14 ([@bibr3-0022155412467635]; [@bibr50-0022155412467635]). Furthermore, MMPs participate in the angiogenic switch because they increase the bioavailability of VEGF and other angiogenic factors by degradation of extracellular components, such as collagen type IV, that bind these factors ([@bibr6-0022155412467635]).

On the other hand, tip cells produce, in cooperation with pericytes, basal lamina components, which may serve as a template for follower stalk cells. To provide structural and organizational stability and to change the endothelial phenotype to a quiescent one, the endothelial tube is ensheathed by a new basal lamina (reviewed in [@bibr26-0022155412467635]). The basal lamina consists of a scaffold of laminins together with essential components, such as collagen IV, perlecan, nidogens, and collagen XVIII. Tip cells recruit and activate pericytes to upregulate expression of transforming growth factor-beta (TGF-β), which induces the production of basal lamina components ([@bibr96-0022155412467635]).

Apart from its function as a scaffold and as a reservoir for growth factors, the extracellular matrix also provides positional information to tip cells and stalks cells. Cues from matrix proteins are transmitted to cells by integrins, which are transmembrane α and β heterodimers that convey signals regulating endothelial morphogenetic events ([@bibr28-0022155412467635]). There are 18 α integrin subunit family members and 8 β integrin subunit family members, and 24 αβ combinations are known to exist ([@bibr31-0022155412467635]). For angiogenesis, the α2β1 and α6β1 integrins are important. Ligation of these integrins induces DLL4/Notch signaling in endothelial cells, and a role of extracellular matrix proteins in the processes controlling tip cell versus stalk cell phenotype has also been suggested ([@bibr28-0022155412467635]).

Recruitment of Pericytes {#section13-0022155412467635}
------------------------

Pericytes are indispensable as they provide pro-survival factors and anti-proliferative factors that stabilize newly formed vessels, and they prevent vessel regression. However, the hypothesis that pericyte loss initiates the first steps of angiogenesis whereas pericyte recruitment occurs only when angiogenesis is completed remains controversial, because large amounts of pericytes are found in endothelial sprouts in vivo ([@bibr69-0022155412467635]; [@bibr75-0022155412467635], [@bibr76-0022155412467635]; [@bibr100-0022155412467635]).

Pericytes are present in early stages of angiogenesis, enabling stimulation of endothelial cell migration ([@bibr69-0022155412467635]; [@bibr75-0022155412467635], [@bibr76-0022155412467635]; [@bibr100-0022155412467635]). The expression of proteases and proteoglycans by pericytes at the tip of vascular sprouts facilitates tip cell motility. Expression of MMPs, particularly MMP14, is coordinated by interactions between endothelial cells and pericytes ([@bibr103-0022155412467635]). Once vessels have been established in the retina, pericytes are necessary for vessel stabilization. Pericyte-endothelial cell interactions result in the expression of tissue inhibitors of MMPs (TIMPs), reducing proteolysis, and subsequently stabilizing vessels ([@bibr72-0022155412467635]).

Recruitment of pericytes is controlled by PDGF-B signaling and angiopoietin-1 (ANGPT1) and ANGPT2 interactions with their receptor TIE2 (reviewed in [@bibr40-0022155412467635]). PDGFs are present as heterodimers (PDGF-AB) or homodimers composed of subunits A and B. Endothelial tip cells of growing vascular sprouts generate a PDGF-B concentration gradient that promotes the recruitment of pericytes expressing the PDGF-B receptor. ANGPT1 expressed by pericytes binds to and activates the TIE2 receptor on endothelial cells, thereby promoting pericyte attachment to capillaries. ANGPT2, a prominent marker of tip cells, was shown to have an antagonizing effect on TIE2, acting as an endogenous dominant negative ligand for ANGPT1. High levels of VEGF and elevated ANGPT2 levels destabilize vessels, causing endothelial cell proliferation and pericyte activation ([@bibr20-0022155412467635]; [@bibr88-0022155412467635]; [@bibr40-0022155412467635]). These two mechanisms together induce the timely detachment and attachment of pericytes in the process of vascular sprouting, allowing tip cells to migrate.

Therapeutic Strategies for Targeting Endothelial Tip Cells {#section14-0022155412467635}
==========================================================

Therapeutic targeting of angiogenesis is an attractive strategy in treating ocular diseases that are driven by pathological neovascularization. Anti-angiogenic agents currently in clinical development interfere with pro-angiogenic growth factors, their receptors, or the downstream signaling. Employing this strategy, the presently registered anti-VEGF drugs have made a significant advance in treating ocular neovascularization.

However, there are a number of reports arguing against anti-VEGF therapy. First, repeated monthly intravitreal anti-VEGF injections cause a tremendous burden on patients and national health care systems. Second, VEGF and its receptors have physiological functions in the normal retina, and blocking VEGF signals interferes with these functions ([@bibr8-0022155412467635]; [@bibr101-0022155412467635]; [@bibr70-0022155412467635]). Third, there is increasing evidence that angiogenesis can occur in the absence of VEGF signaling ([@bibr5-0022155412467635]). Fourth, adverse effects, such as promotion of fibrosis, scarring, and tractional retinal detachment, have been reported after intravitreal anti-VEGF injections due to the shift in the balance between VEGF and connective tissue growth factor (CTGF, also known as CCN2), which induces the angiofibrotic switch ([@bibr57-0022155412467635], [@bibr58-0022155412467635]; [@bibr97-0022155412467635]). Therefore, there is a great therapeutic demand and scope for identifying new determinants of angiogenesis besides anti-VEGF therapy that may ultimately translate into more effective and efficient therapies with less adverse effects.

Ideally, agents that primarily target tip cells and do not interfere with quiescent endothelium should block pathological angiogenesis in the retina efficiently and safely with less adverse effects. The tip cell gene expression pattern ([Table 1](#table1-0022155412467635){ref-type="table"}) that is known now should facilitate the development of such therapeutic strategies. Promising agents specifically targeting tip cells are now in clinical trials or may be in the near future.

The VEGF-DLL4-Notch signaling axis in angiogenesis is a major focus of research for the development of novel therapies (reviewed in [@bibr67-0022155412467635]). Blockade of DLL4/Notch signaling enhances the chaotic, nonproductive vascular sprouting that is characteristic of tumor angiogenesis by promoting VEGF-driven tip cell formation and vascular leakage ([@bibr49-0022155412467635]). These events lead to disrupted neovascular perfusion, starvation of the tumor, and delay in tumor growth ([@bibr22-0022155412467635]; [@bibr49-0022155412467635]). Therapeutic options in the DLL4-Notch-VEGF pathway were also studied in the mouse oxygen-induced retinopathy model. Interestingly, the intravitreal injection of a soluble DLL4 fusion protein, which attenuates DLL4/Notch signaling, stimulated extension of new vascular sprouts in the retina and limited ectopic growth of pathological neovascular tufts into the vitreous ([@bibr60-0022155412467635]).

A well-tolerated DNA vaccination strategy, targeting endothelial tip cells through the antigen DLL4, showed similar therapeutic efficacy in mouse tumor models ([@bibr39-0022155412467635]). In this study, a DLL4-plasmid vaccine was generated and injected three times in mice to induce the production of antibodies recognizing the extracellular domain of DLL4, resulting in a retarded growth of implanted mammary carcinomas in these mice by induction of a non-productive angiogenic response. Blocking of the DLL4-Notch-VEGF pathway through injections of anti-DLL4 (together with anti-VEGF) antibodies or via the induction of immunity toward tip cells may provide protection against recurrent proliferative retinopathies or may reduce the necessity of monthly anti-VEGF injections.

PDGF is secreted by tip cells to recruit pericytes; blocking PDGF through injections of anti-PDGF antibodies results in immature blood vessels that lack pericytes. A recent clinical phase 2b trial of anti-PDGF therapy administered in combination with anti-VEGF therapy showed statistically significant superior efficacy over anti-VEGF monotherapy for the treatment of neovascular AMD (<http://clinicaltrials.gov/ct2/show/record/NCT01089517>).

VEGFR3 kinase activity inhibitors but not ligand-blocking antibodies suppressed the sprouting of endothelial cells that had low Notch signaling activity ([@bibr92-0022155412467635]; [@bibr105-0022155412467635]). In settings of low Notch activity, VEGFR3 upregulation allows strong, ligand-independent and highly deregulated angiogenesis even in the absence of VEGF-VEGFR2 signaling ([@bibr5-0022155412467635]). Neutralizing antibodies against VEGFR3 ligands VEGF-C and VEGF-D therefore showed minimal or no effect on tumor angiogenesis. Recently, it has been proposed that VEGFR3 exerts its function in angiogenesis indirectly by regulating the level of VEGFR2 activation, providing an additional layer of control over VEGFR2-mediated signals ([@bibr105-0022155412467635]). Therefore, simultaneous blocking of VEGFR2 and VEGFR3 may be beneficial in the treatment of ocular neovascularization. Probing the status of vascular Notch or VEGFR3 activation may be relevant in patients who only partially respond to anti-VEGF treatment or do not respond at all ([@bibr5-0022155412467635]; [@bibr105-0022155412467635]).

EFNB2, the ligand for EphB4, was found to be upregulated in tip cells ([@bibr83-0022155412467635]), where it controls the function of VEGFR2 and VEGFR3 ([@bibr73-0022155412467635]; [@bibr98-0022155412467635]). DLL4/Notch and EFNB2/EphB4 pathways play critical roles in tumor vessel development; combinational targeting of both pathways was shown to be highly effective in disrupting tumor angiogenesis ([@bibr21-0022155412467635]). Endogenous EFNB2 and EphB4 are regulators of retinal neovascularization during oxygen-induced retinopathy and may be useful targets for therapeutic intervention, alone or in combination with other therapies ([@bibr104-0022155412467635]; [@bibr18-0022155412467635], [@bibr17-0022155412467635]; [@bibr1-0022155412467635]).

APLN is an endogenous ligand for the angiotensin-1-like receptor APJ that induces proliferation of endothelial cells. APLN is an angiogenic factor in retinal endothelial cells, and loss of APLN-APJ signaling results in retardation of developmental retinal angiogenesis ([@bibr71-0022155412467635]; [@bibr52-0022155412467635], [@bibr51-0022155412467635]; [@bibr94-0022155412467635]). Moreover, it has been shown that APLN acts as a potent activator of tumor angiogenesis ([@bibr85-0022155412467635]). Several recent studies identified APLN expression to be upregulated in tip cells, whereas its receptor APJ was found to be expressed in stalk cells ([@bibr20-0022155412467635]; [@bibr88-0022155412467635]; [@bibr83-0022155412467635]). Based on these findings, APLN-APJ signaling has been suggested to stimulate stalk cell proliferation controlled by tip cells. Blocking the APLN-APJ pathway may prevent stalk cell proliferation and sprout elongation ([@bibr94-0022155412467635]).

Production of ANGPT2 by endothelial cells stimulates angiogenesis in the presence of VEGF. ANGPT2 plays an important role in physiological and pathological retinal angiogenesis ([@bibr37-0022155412467635]; [@bibr91-0022155412467635]), and increased expression of ANGPT2 relative to ANGPT1 in tumors correlates with poor prognosis (reviewed in [@bibr44-0022155412467635]). Several recent studies identified ANGPT2 expression to be specifically upregulated in tip cells ([@bibr20-0022155412467635]; [@bibr83-0022155412467635]). Another recent study showed that a neutralizing antibody specific for ANGPT2 inhibits ocular angiogenesis ([@bibr68-0022155412467635]). Agents targeting ANGPT2 signaling in tumor angiogenesis are now under development, and some have reached the level of phase 2 clinical trials ([@bibr44-0022155412467635]).

CXCR4, the receptor for stromal cell-derived factor-1 (SDF1; also known as CXCL12), was found to be abundantly expressed in tip cells ([@bibr88-0022155412467635]; [@bibr95-0022155412467635]; [@bibr83-0022155412467635]). SDF1/CXCR4 signaling also contributes to the activation of resident macrophages (also called microglia) that promote neovascular sprouting in the retina through secretion of VEGF ([@bibr79-0022155412467635]; [@bibr95-0022155412467635]). Inhibition of CXCR4 signaling by neutralizing antibodies against SDF1 or antagonists of the CXCR4 receptor in neonatal mice resulted in defects in retinal tip cell morphology ([@bibr79-0022155412467635]; [@bibr88-0022155412467635]; [@bibr95-0022155412467635]). Moreover, SDF1 levels increased after chemotherapy and anti-VEGF therapy, favoring tumor recurrences ([@bibr102-0022155412467635]). CXCR4 is also present in hematopoietic stem cells, and receptor activation stimulates homing of these cells in the bone marrow; in this context, CXCR4 antagonists are now approved for mobilization of stem cells for autologous and allogenic transplants in patients with leukemia (reviewed in [@bibr25-0022155412467635]). Clinical trials combining anti-VEGF and CXCR4 antagonists are now under development to block tumor angiogenesis. Treatment using CXCR4 antagonists in combination with other therapies may be an interesting strategy to prevent recurrent neovascularization also in the context of proliferative retinopathies.

Conclusions and Future Directions {#section15-0022155412467635}
=================================

Understanding the complex interrelated directions of endothelial cell differentiation in the angiogenic processes and the molecular mediators involved has led to the development of strategies specifically targeting endothelial tip cells and to the screening of novel potential anti-angiogenic agents. Angiogenesis inhibitors targeting tip cells without affecting quiescent endothelial cells or their functions are likely to change the face of medicine in the next decade. The challenge for the future is to develop such novel anti-angiogenic strategies and to optimize combination treatment regimens to fully exploit the therapeutic potential of angiogenesis inhibition.
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